Eocene, Barcode develop Aramchol nanoparticle formulation targeting liver, GI tumor microenvironment
EOCN•Eocene reported development of a tumor-targeted lipid nanoparticle formulation of Aramchol through subsidiary Galmed’s collaboration with Barcode Nanotech. The formulation aims to target fibrosis-driving cells in liver and gastrointestinal tumors.
1. Formulation development
Eocene reported development of a tumor-targeted lipid nanoparticle formulation of Aramchol through subsidiary Galmed’s collaboration with Barcode Nanotech. It aims to target fibrosis-driving cells in liver and gastrointestinal tumors, potentially improving responses to immunotherapy and other standard treatments.
2. Prior clinical findings
Previously reported clinical findings showed oral Aramchol improved liver fibrosis in NASH/MASH patients in the ARREST trial and ARMOR open-label extension.




